PierianDx has reached an agreement with Washington University to license a genetic testing tool that could speed patient diagnosis and treatments based on an individual’s DNA.
Terms of the deal were not disclosed.
The technology, called the Clinical Genomicist Workstation, was a “revenue producing asset” for Washington University for several years, and will help PierianDx generate a “significant positive revenue stream” in 2014, according to a PierianDx spokeswoman.